Browse EX-10 agreements

Execution Version

SECURITY AGREEMENT

This SECURITY AGREEMENT, dated as of August 15, 2026 (this “Agreement”), is by and between Abundia Global Impact Group, Inc., a Delaware corporation (the “Company” or the “Debtor”), and Bower Family Holdings, LLC, (“BFH,” and the “Secured Party”) and the holder of the Company’s Secured Note due August 15, 2028 following its date of issuance, in the original aggregate principal amount of up to $10 million (the “Note”).

W I T N E S S E T H:

WHEREAS, pursuant to the Purchase Agreement (as defined in the Note), the Secured Party has agreed to extend the loan to the Company evidenced by the Note;

WHEREAS, in order to induce the Secured Party to extend the loan evidenced by the Note under the Purchase Agreement, the Debtor has agreed to execute and deliver to the Secured Party this Agreement and to grant the Secured Party a security interest in certain property of the Debtor to secure the prompt payment, performance and discharge in full of all of the Company’s obligations under the Note.

…

Execution Version

SECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this “Agreement”) is dated as of August 15, 2026, by between Abundia Global Impact Group, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

ARTICLE I.

DEFINITIONS

…

**Confidential **

**FORM OF LOCK-UP AGREEMENT **

August 16, 2026

Fulcrum Therapeutics, Inc.

26 Landsdowne Street

Cambridge, MA 02139

Ladies and Gentlemen:

The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Fulcrum Therapeutics, Inc., a Delaware corporation (“Parent”), is entering into an Agreement and Plan of Merger, dated as of August 16, 2026 (as the same may be amended from time to time, the “Merger Agreement”) with Fusion Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, Fusion Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent, and Slate Medicines, Inc., a Delaware corporation (the “Company”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.

…

**REGISTRATION RIGHTS AGREEMENT **

**THIS REGISTRATION RIGHTS AGREEMENT **(this “Agreement”), dated as of August 16, 2026, is entered into by and among Slate Medicines, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among the Company and the parties hereto, dated as of August 16, 2026 (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).

**WHEREAS: **

…

**SECURITIES PURCHASE AGREEMENT **

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 16, 2026, by and among Slate Medicines, Inc., a Delaware corporation (the “Company”), and each of the Persons listed on Exhibit*** A* attached to this Agreement (each, an “Investor” and together, the “Investors”).

WHEREAS, the Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the U.S. Securities Act of 1933, as amended (the “Securities Act”);

WHEREAS, the Company desires to sell to the Investors, and each Investor desires to purchase from the Company, severally and not jointly, upon the terms and subject to the conditions stated in this Agreement, shares (the “Initial Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a per share purchase price equal to the Share Price;

…

**CONFIDENTIAL **

**COMPANY SUPPORT AGREEMENT **

This *SUPPORT AGREEMENT (this “Agreement”) is made as of August 16, 2026, by and between **FULCRUM THERAPEUTICS, INC.**, a Delaware corporation (“Parent”), and the [Person] set forth on *Schedule** A hereto (the “Stockholder”).

WHEREAS, as of the date hereof, the Stockholder is the holder of the number of shares of common stock, par value $0.00001 per share (“Common Stock”), preferred stock, par value $0.00001 per share (“Preferred Stock” and collectively with the Common Stock, the “Company Shares”) and Company Options to acquire the number of Company Shares, of SLATE MEDICINES, INC., a Delaware corporation (the “Company”), set forth opposite the Stockholder’s name on Schedule*** A* (all Company Shares owned by the Stockholder, or hereafter issued pursuant to securities exercisable or convertible to or otherwise acquired, whether beneficially or of record, or owned by the Stockholder prior to the termination of this Agreement, as well as shares set forth on Schedule***

…

**CONFIDENTIAL **

**PARENT SUPPORT AGREEMENT **

This *SUPPORT AGREEMENT (this “Agreement”) is made as of August 16, 2026, by and between **SLATE MEDICINES, INC.**, a Delaware corporation (the “Company”), and the Person set forth on *Schedule** A hereto (the “Stockholder”).

WHEREAS, as of the date hereof, the Stockholder is the holder of the number of shares of common stock, par value $0.001 per share (the “Parent Shares”) and Parent Options or Parent Restricted Stock Unit Awards to acquire the number of Parent Shares, of FULCRUM THERAPEUTICS, INC., a Delaware corporation (“Parent”), set forth opposite the Stockholder’s name on Schedule*** A* (all Parent Shares owned by the Stockholder, or hereafter issued pursuant to securities exercisable or convertible to or otherwise acquired, whether beneficially or of record, or owned by the Stockholder prior to the termination of this Agreement, as well as shares set forth on Schedule*** A*, being referred to herein as the “Subject Shares”);

…

**TRANSITION AGREEMENT AND GENERAL RELEASE **

This Transition Agreement and General Release (this “Agreement”) is made by and between Karen Alexander (“Executive”) and Bakkt, Inc., f/k/a Bakkt Holdings, Inc. (the “Company”) (together, with its parents, subsidiaries, divisions, affiliates, related business entities, successors, and assigns, and any of the respective affiliates of the Company, including, without limitation, Bakkt Opco Holdings, LLC and Bakkt, LLC, the “Company Group”) (the Company and Executive are jointly referred to as the “Parties” or individually referred to as a “Party”).

**RECITALS **

WHEREAS, Executive has been employed by the Company, most recently serving as its Chief Financial Officer;

WHEREAS, Executive and the Company entered into an Employment Agreement dated as of October 12, 2022, with an effective date of August 8, 2022, which amended and restated an employment agreement between Executive and the Company dated March 9, 2022, as amended June 9, 2022 (as amended and restated, the “Employment Agreement”);

…

**BAKKT, INC. **

**EMPLOYMENT AGREEMENT **

**FOR **

**MATTHEW WHITE **

This is an Employment Agreement (the “Agreement”), dated as of August 11, 2026, by and between Bakkt, Inc., a Delaware corporation (together with its direct and indirect subsidiaries, the “Company”), and (ii)** Matthew White** (“Executive”), the terms and conditions of which are as follows:

**Agreement **

1. Term. Subject to the terms and conditions set forth in this Agreement, the Company agrees to employ Executive, and Executive agrees to be employed by the Company, for a term which shall start on August 17, 2026 (the “Effective Date”) and shall continue until this Agreement is terminated as provided herein (the period of effectiveness of this Agreement, the “Term”).

…

SEPARATION AGREEMENT

This Separation Agreement (this “Agreement”), dated as of August 16, 2026, is entered into between L3Harris Technologies, Inc., a Delaware corporation (the “Company”) and Christopher Kubasik (the “Executive” or “you”).

WHEREAS, the independent members of the Board of Directors of the Company (the “Board”) became aware of certain conduct by the Executive that was not consistent with the values of the Company as outlined in its Code of Conduct, which conduct was unrelated to the Company’s financial reporting, controls, customer relations or operational performance;

WHEREAS, the Board, following its review of these matters and consultation with outside counsel to the Company, in the exercise of its business judgment, has determined that reaching an agreement with the Executive regarding his departure from the Company on the terms set forth herein is in the best interests of the Company and its stockholders, and accordingly, the Company is not pursuing termination of the Executive’s employment for “cause”; and

…

---

Exhibit 10.1

Execution Version

THIRD AMENDMENT TO

AMENDED AND RESTATED CREDIT AGREEMENT

This THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) is executed as of August 14, 2026 to be effective for all purposes as of June 30, 2026, among PRAIRIE OPERATING CO., a Delaware corporation (the “Borrower”), each other Credit Party party hereto, each of the Lenders party hereto and CITIBANK, N.A., as administrative agent (in such capacity, together with its successors in such capacity, the “Administrative Agent”).

RECITALS

…

August 17, 2026

3i, LP

2 Wooster Street, 2nd Floor

New York, NY 10013

Attention: Maier J. Tarlow

Re:	Side Letter — Closings under Series B Preferred Purchase Agreement

Dear Mr. Tarlow:

This letter agreement (this “Letter Agreement”) is entered into as of the date first written above, by and between Valion Bio, Inc., a Delaware corporation (the “Company”), and 3i, LP, a Delaware limited partnership (the “Purchaser”).

…